madman
Super Moderator
Preliminary results of clinical study of Medherant’s testosterone patch for post-menopausal women
Medherant’s testosterone TEPI Patch has been well-tolerated and has demonstrated excellent wearability. Medherant is planning for further clinical evaluation of the testosterone TEPI Patch that is being developed for treatment of hypoactive sexual desire disorder, or distressing low libido, in...
10 April 2024 (Coventry, UK). Medherant is pleased to announce the preliminary results of the Phase I study of its testosterone patch technology being conducted at Hammersmith Medicines Research (HMR; London). Preliminary results from this study demonstrate the delivery of testosterone to post-menopausal women to achieve blood levels similar to those in pre-menopausal women.
Medherant’s testosterone TEPI Patch has been well-tolerated and has demonstrated excellent wearability.
Medherant is planning for further clinical evaluation of the testosterone TEPI Patch that is being developed for treatment of hypoactive sexual desire disorder, or distressing low libido, in post-menopausal women. Medherant is also considering clinical studies to investigate other potential benefits of testosterone therapy.
“This signals a significant step towards developing a licensed product for addressing post-menopausal women's health needs,” says Karolina Afors, Medherant’s Medical Director. “We look forward to advancing our research and contributing meaningfully to the field of women's health.”
